Dear colleagues,

many physicians have recently contacted the European Society of Urogenital Radiology about guidelines on gadolinium-based contrast agents and nephrogenic systemic fibrosis. After much discussion, the majority of academic members have agreed on guidelines concerning this issue, which we are pleased to release. We hope you find it helpful.

Please don’t forget to report cases to nsf(a)esur.org. The European Medicines Agency has updated the SPC’s on gadolinium-based contrast agents per June 26^th, 2007. The new documents, including the public assessment report as well as Q&A, can also be found on this page.

Yours sincerely,

Gertraud Heinz-Peer M.D.

ESUR Secretary/Treasurer

1. Commission on Human Medicines on NSF (26 June 2007)

2. Questions & Answers: NSF & Gadolinium (26 June 2007)

3. Public Assessment Report: NSF & Gadolinium (26 June 2007)

Please note: The first three are EMEA documents and are available in all European languages at the National Medicines Agencies --> LINK.

a. ESUR NSF Guidelines (17 July 2007)

b. Click here for more information provided by Henrik S. Thomsen (July 2007)

c. European Radiology, News from the ESUR (Sept. 2007)

!NEW! d. Pediatric NSF Statement 2007 (Pediatric Uroradiology, 2^nd revised Edition, edited by R. Fotter, Springer 2008, p 516-517)

CLICK HERE TO REPORT NSF